PTSM: Pharmaceutical Technology Sourcing and Management, May 7, 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, May 7, 2014
API Synthesis & Manufacturing
Process Design Is Critical for Commercial Manufacture of HPAPIs
By Cynthia Challener, PhD
Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.
Outsourcing
Outsourcing Remains Strong In Traditional Areas
By Eric Langer
Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.
Drug Delivery
Packaging Becomes Enabler for Biopharmaceuticals
By Cynthia Challener, PhD
Once an afterthought, packaging has now become an essential component of biopharmaceutical product development and marketing.
Supply Chain
Using eClinical Systems for Supply-Chain Management
By Kurt Lumsden
Kurt Lumsden, Director, eCDS Client Services at PAREXEL Informatics, discusses eClinical supply-chain management.
FDA and Industry Take Action for a More Secure Drug Supply Chain
By Jill Wechsler
New identifiers and tracking requirements aim to block illegitimate products.
Business
US Biopharma Worries About Losing Lead in Innovation
By Rita Peters
Changes are needed to maintain US biopharma innovation leadership.
Global Instability Impacts Brazil's Pharma Market
By Hellen Berger
How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?
Contract Services
Capsugel Enters Agreement with Chiasma to Manufacture Oral Octreotide Acetate
By Melanie Sena
Capsugel enters an agreement with Chiasma to increase manufacturing operations for octreotide, a treatment for acromegaly.
Azzur Group and BioSPEQ Announce Merger
By Melanie Sena
The Azzur Group and BioSPEQ merger will increase consulting services and project resources within the life-sciences industry.
UPM to Manufacture Products For Amerigen Pharmaceuticals
By Melanie Sena
UPM will commercially manufacture two ANDA products for Amerigen Pharmaceuticals.
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
By Melanie Sena
Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.
Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical
By Melanie Sena
Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.
News
BASF Builds New Plant in Germany
By Melanie Sena
BASF builds a new plant for specialty amines in Ludwigshafen, Germany.
Colorcon Opens Major Facility in India
Colorcon invests in significant expansion of its South Asia production facility.
Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies
By Melanie Sena
Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.
CSR and Sustainability Forum
Novartis Publishes eBook of Meningococcal Disease Survivors
By Melanie Sena
Novartis' eBook features images of meningococcal disease survivors from around the world.
Bristol-Myers Squibb Named First on 2014 Best Corporate Citizens List
By Melanie Sena
Bristol-Myers Squibb is named No. 1 on 2014 Best Corporate Citizens List for the third time in six years.
Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association
By Melanie Sena
Janssen Pharmaceutical collaborates with Stop TB Partnership's Global Drug Facility to increase access to anti-TB compound.
Eli Lilly Launches Second Education Program for Medical Students
By Melanie Sena
Eli Lilly has developed the Lilly Medical Student Intern Program for future physicians.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here